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[a] Ralph Weissleder,
[b] Jason S. Lewis,*
[a, c] and
Thomas Reiner*
[a]
The need for post-synthetic modifications and reactive pros-
thetic groups has long been a limiting factor in the synthesis
and study of peptidic and peptidomimetic imaging agents. In
this regard, the application of biologically and chemically or-
thogonal reactions to the design and development of novel ra-
diotracers has the potential to have far-reaching implications
in both the laboratory and the clinic. Herein, we report the
synthesis and development of a series of modular and versatile
building blocks for inverse electron-demand Diels–Alder
copper-free click chemistry: tetrazine-functionalized artificial
amino acids. Following the development of a novel peptide
coupling protocol for peptide synthesis in the presence of tet-
razines, we successfully demonstrated its effectiveness and ap-
plicability. This versatile methodology has the potential to
have a transformational impact, opening the door for the
rapid, facile, and modular synthesis of bioorthogonally reactive
peptide probes.
Over the last two decades, low-molecular-weight peptides
have received increasing interest as vectors for the delivery of
diagnostic and therapeutic payloads to tumors. Indeed, the
high specificity and selectivity, short blood half-life and rapid
excretion profile have made short oligopeptides particularly at-
tractive in the realm of nuclear medicine, specifically positron
emission tomography (PET) imaging. Radiolabeled variants of
several tissue-specific peptides have been successfully synthe-
sized and validated in vitro and in vivo, including
18F- and
64Cu-labeled peptides that target the somatostatin receptor
type 2 (sstr),
[1] the gastrin-releasing peptide receptor (GRPr),
[2]
and the glucagon-like peptide 1 receptor (GLP1-R).
[3]
However, even after a worthwhile biomarker and a specific
and selective targeted peptide have been identified, one of
the most common challenges in the development of novel
PET imaging agents is the identification of a rapid, efficient,
and high-yielding method for the conjugation of a radionuclide
to the peptide in question. The most common synthetic strat-
egy for the radiolabeling of peptides is the post-synthetic con-
jugation of a reactive prosthetic group or radiometal chelator
to an intact peptide, followed by a subsequent radiolabeling
reaction (Scheme 1A). To this end, prosthetic groups and che-
lators have been appended to peptides by a wide variety of
methods, yet three strategies for conjugation based on natu-
rally occurring amino acids stand as the most common routes:
(1) peptide bond formation between an activated carboxylic
acid (e.g., a succinimidyl ester) and an amine, (2) thioether for-
mation via reaction of a thiol and a maleimide, and (3) thiourea
bond formation via reaction of an isothiocyanate and a primary
amine. Each of these methods is dependent on the reactivity
of either lysines (amines) or cysteines (thiols).
[4,5] While the
Scheme 1. Conceptual synthesis of tetrazine-amino acid incorporation into
peptides. A) The late stage incorporation of an orthogonal reactive group,
a common synthetic route for the construction of targeted peptides: pep-
tides are synthesized using SPPS and subsequently derivatized using bifunc-
tional prosthetic groups that react selectively or semi-selectively with bio-
genic amino acids. B) The incorporation of an orthogonal reactive group
into peptides via tetrazine-bearing amino acids: tetrazine-bearing amino
acids are employed in a manner identical to biogenic amino acids and incor-
porated during SPPS. After cleavage of the peptide from the solid support,
the tetrazine-bearing amino acids can serve as chemically orthogonal
groups that react at radiochemically relevant concentrations, yielding target-
ed imaging agents quickly and selectively.
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acids has proven effective in a variety of settings, it is not with-
out significant limitations. The late-stage incorporation of
a prosthetic group or chelator requires additional synthetic
steps that can add complexity and reduce yield. In addition,
the use of naturally occurring amino acids as conjugation han-
dles often renders the selective and site-specific at-
tachment of radionuclides difficult, since multiple re-
active amino acids can be present in a single biomol-
ecule.
[5,6] Furthermore, the modification of natural
amino acids in a peptide risks compromising the bio-
logical reactivity of the biomolecule. Finally, labeling
naturally occurring amino acids necessarily reduces
the number of biogenic residues that remain avail-
able for inclusion in a peptide, in turn putting strain
on the design of targeted biomolecules.
Recent years, however, have witnessed a move
beyond naturally occurring amino acids, with an in-
creasing amount of focus on the use of artificial
amino acids bearing orthogonal functional groups.
Along these lines, we have hypothesized that the in-
verse electron-demand Diels–Alder cycloaddition be-
tween tetrazine and trans-cyclooctene offers a near
ideal strategy for the site-selective labeling of bio-
molecules.
[7] Indeed, the rapidity, chemoselectivity,
and bioorthogonality of this emergent click ligation
make it particularly well suited to bioconjugation ap-
plications and especially radiochemistry.
[8,9]
Herein, we report the design, development, and
validation of a synthetic strategy that inverts the tra-
ditional peptide modification paradigm: the incorpo-
ration of bioorthogonal tetrazine-bearing amino
acids into peptides via solid-phase peptide synthesis
(SPPS). We contend that the incorporation of a reac-
tive tetrazine moiety into a peptide at the initial
stage of peptide synthesis rather than in a post-syn-
thetic modification offers maximal versatility, modu-
larity, and facility. As an initial proof of concept, we
have created a bioorthogonally reactive pentapep-
tide using a trifunctional tetrazine-containing amino
acid derivative that is compatible with SPPS (Scheme 1B).
Indeed, this artificial amino acid can be incorporated into
a peptide chain in a manner identical to naturally occurring
amino acids via the coupling, deprotection, and cleavage reac-
tions of SPPS.
This technology offers a number of critical advantages over
nonspecific methodologies that rely on the late-stage incorpo-
ration of an orthogonal moiety or prosthetic group. Specifical-
ly, this strategy eliminates an additional step in the synthesis
of the radiolabeled probe: the conjugation of the orthogonal
group to the peptide. The incorporation of an orthogonal
group at such an early stage also allows for precise control
over the molecular location of the radiolabel in the primary se-
quence of the peptide. And finally, the use of a tetrazine-bear-
ing amino acid precludes the need to dedicate specific amino
acids for derivatization, thereby freeing all of the biologically
available amino acids for use in the peptide in question.
The first step in the creation of this system was the synthesis
of a series of tetrazine-bearing amino acid derivatives. To this
end, all of the functionalized amino acids were derived from
l-lysine and fully characterized using HPLC, LC–ESI-MS, HRMS
and NMR spectroscopy. To synthesize the tert-butoxycarbonyl
(Boc)-protected amino acid Boc-t-OH (1 Figure 1D), a previous-
ly published carboxylic acid-bearing tetrazine
[10] (Tz-COOH) was
reacted with N-hydroxysuccinimide (NHS) in the presence of
the coupling agent N-(3-dimethylaminopropyl)-N’-ethylcarbo-
diimide hydrochloride (EDCI). The resulting Tz-NHS ester was
isolated using silica gel chromatography and reacted with Boc-
Lys-OH, affording 1 as a pink film in 50% yield.
The stability of the tetrazine-bearing amino acids under the
various reaction conditions of SPPS was paramount to the suc-
cess of the system. Not surprisingly, potential pitfalls were
found at each of the SPPS steps: deprotection, coupling, and
cleavage from the resin. The two most common protecting
group methodologies used to generate peptides using SPPS
are the Boc- and 9-fluorenylmethoxycarbonyl (Fmoc)-based
strategies. For the synthesis of tetrazine-labeled peptides, Boc-
protected amino acids are the most suitable option, for their
removal is based on non-reducing acids (typically trifluoroace-
tic acid, TFA), and solvents in which reduction-prone tetrazines
Figure 1. Stability of tetrazine-bearing amino acids under SPPS conditions: A) amino acid
coupling conditions; B) N-Boc deprotection conditions; C) resin cleavage conditions.
E) Structure of the novel tetrazine-pentapeptide VFtAG. F) HPLC trace of the pentapep-
tide VFtAG before and after HPLC purification.
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quire piperidine or other nucleophilic bases for the removal of
the Fmoc protecting group, reagents that are generally incom-
patible with the tetrazine moiety. Further, we found that tetra-
zines decompose in the presence of the common coupling
agents 1-hydroxybenzotriazole (HOBt) and N,N’-diisopropylcar-
bodiimide (DIC) but are stable in the presence of H nig’s base
(N,N-diisopropylethylamine, DIEA) and (benzotriazol-1-yloxy)-
tris(dimethylamino)phosphonium hexafluorophosphate (BOP).
Finally, SPPS via the Boc-based strategy often requires strong
acids for the cleavage of the synthesized peptides from the
resin, most commonly HF, HBr, or trimethylsilyl trifluorometha-
nesulfonate. Unfortunately, none of these options represents
a suitable choice. HF is highly toxic, and the necessary associat-
ed specialized equipment might hamper the synthesis of tetra-
zine-labeled peptides in biomedical research laboratories. The
two other cleavage reagents lead to complete decomposition
of the tetrazine. In order to prevent this, we turned to micro-
wave-assisted cleavage of the peptide from the resin. Micro-
wave-assisted synthetic transformations have been used
before to mediate resin-associated reactions,
[11] and they have
shown to be successful for peptide cleavage as well.
[12]
To test the stability of the tetrazines under amino acid cou-
pling conditions, Tz-NHS ester was reacted with methoxy-pro-
tected Boc-Lys-OMe, preventing the activation and thus the
derivatization of the carboxylic acid. The resulting Boc-t-OMe
(2, Figure 1D) was dissolved in a freshly prepared mixture of
BOP (10 mm) and DIEA (100 mm)i nN,N-dimethylformamide
(DMF). The decomposition of 2 was measured using HPLC
against a coumarin standard. The decomposition rate was
found to be linear with a half-life (t1/2) of 80.4 h (Figure 1A).
Under these conditions, each coupling reaction (60 min) would
cause a decomposition of only 0.61 0.25%.
The stability of the tetrazine under deprotection conditions
was measured using H-t-OH (3), which was generated from
Boc-t-OH (1) in 72% isolated yield via deprotection with TFA/
CH2Cl2 (1:1). Similar to the coupling conditions test, the stabili-
ty of 3 was measured using HPLC against a coumarin standard.
In 95% TFA, the half-life (t1/2) was 104.2 h (Figure 1B). This, in
turn, results in each deprotection reaction (25 min) causing
0.20 0.11% of the tetrazine to decompose.
For the cleavage of tetrazine-containing peptides from the
resin, microwave-assisted acidic cleavage was chosen, a tech-
nique which has been previously employed in SPPS as a mild
cleavage technique.
[12] The deprotected tetrazine-bearing
amino acid H-t-OH (3) was dissolved in a mixture of TFA and
water (97.5% TFA) and subjected to 50 MW microwave irradia-
tion. Again, the results were analyzed by HPLC, and coumarin
served as an internal standard. Under these conditions, the
half-life (t1/2)o f3 was observed to be 129.8 min (Figure 1C).
Consequently, during a cleavage procedure employing these
conditions (2 5 min), an estimated 7.5 2.5% of the orthogo-
nal group on the immobilized peptide would decompose. Cou-
pling efficiencies using only naturally occurring amino acids
and standard protocols are typically around 99%, which illus-
trates that the measured decomposition rates are well within
an acceptable range. Based on these decomposition rates, a 14
amino acid peptide (e.g., a-melanocyte-stimulating hormone,
a-MSH) with a tetrazine in position 7 could be synthesized,
deprotected, and removed from the resin with 85% of the
tetrazines intact. If, however, the tetrazine were placed in
position 14 of the peptide, 81% of the tetrazine in the pep-
tide would remain impact. Alternatively, if the tetrazine-amino
acid were the last residue incorporated, 92% of the cleaved
peptide would contain the reactive functional group. Impor-
tantly, this decomposition would represent a small reduction
in the overall yield of the synthesized peptide but would not
compromise the purity of the peptide after HPLC purification
(Figure 1F).
Using these reaction conditions, we subsequently synthe-
sized a model tetrazine-containing pentapeptide, VFtAG (4,
Figure 1E). The peptide represents a non-targeted amino acid
sequence, chosen to illustrate that the tetrazine-bearing amino
acid can be incorporated centrally in the backbone of a peptide
rather than simply at one of the two termini. It was synthe-
sized using a standard Merrifield-resin, which was preloaded
with glycine (0.01–0.02 mmol scale). The deprotection, cou-
pling, and resin cleavage was conducted according to the con-
ditions delineated above and in Figure 1A–C. After the cleav-
age of the peptide, the crude product was purified using HPLC
and obtained as a light pink solid.
In order to illustrate the potential applications of this tech-
nology in the synthesis of constructs for PET imaging, we next
sought to radiolabel the peptide using the bioorthogonal
chemistry made possible by the tetrazine moiety. To this end,
we first synthesized a trans-cyclooctene (TCO)-bearing deriva-
tive of the
89Zr
4+ chelator desferrioxamine (DFO) via the cou-
pling of an NHS-activated ester of a TCO-COOH moiety with
desferrioxamine mesylate. After the purification of DFO–TCO,
we then radiolabeled the TCO-modified chelator with
89Zr
under standard
89Zr
4+ radiolabeling conditions: incubation in
phosphate-buffered saline at pH 7.2–8.0 for 30 min at 378C.
Following purification via reversed-phase HPLC (C18), the radio-
labeled
89Zr-DFO–TCO construct (5) was isolated in relatively
high yield (39%), high radiochemical purity (>98%), and high
specific activity (5.59 mCimmol
 1). Finally, the rapid and clean
bioorthogonal conjugation between
89Zr-DFO–TCO and VFtAG
was performed in an acidified solution of acetonitrile and
water (1:1, 0.1% TFA, Figure 2A), producing
89Zr-VFtAG (6)i n
>95% radiochemical purity and 65% uncorrected isolated ra-
diochemical yield (RCY; Figure 2B–C).
Ultimately, we believe that this chemical technology has the
potential to have a transformational impact on the synthesis,
development, and optimization of molecular imaging probes
for PET and beyond. In all but the simplest of cases, the incor-
poration of the bioorthogonal tetrazine functionality during
SPPS will reduce complexity, increase yields, and provide signif-
icant flexibility and modularity. In essence, the tetrazine-bear-
ing amino acid—a tri-functional moiety bearing a carboxylic
acid, an amine, and a bioorthogonal tetrazine—can be seen as
an addition to the library of already available natural amino
acids used during SPPS and thus, after cleavage, will yield the
reactive target molecule without further chemical modification
or derivatization.
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eventually be used as building blocks in the combinatorial syn-
thesis of potential biologically active peptides, facilitating the
development of libraries of probes on a fully automated basis
without the need for multiple purification steps after synthesis.
Further, the modularity of the system does not end with the
tetrazine side of the reaction; just as the tetrazine can be in-
corporated into a myriad of different peptide sequences, its
trans-cyclooctene reaction partner can be appended with a tre-
mendous variety of cargoes ranging from radionuclides to flu-
orophores to chemotherapeutics. Currently, efforts are under-
way to optimize the system to increase yields, to utilize this
technology to produce longer, biomarker-targeting, tetrazine-
bearing peptides for PET imaging applications, and to apply
this technology to develop peptides for other molecular imag-
ing modalities, including single-photon emission computed to-
mography (SPECT) and fluorescence imaging.
Experimental Section
Unless otherwise noted, all reagents were purchased from Sigma–
Aldrich (St. Louis, MO, USA) and used without further purification.
Boc-Gly, Merrifield resin and Boc-Lys-OMe were purchased from
Bachem (Torrance, CA, USA). Boc-Ala-OH, Boc-Lys-OH, Boc-Phe-OH
and Boc-Val-OH were purchased from Novabiochem (Merck KGaA,
Darmstadt, Germany). 3-(4-Phenylacetic acid)-1,2,4,5-tetrazine (Tz-
COOH) and (E)-cyclooct-4-enyl 2,5-dioxopyrrolidin-1-yl carbonate
(TCO-NHS) were synthesized as described before.
[10,13] HPLC analy-
ses were performed using a Shimadzu HPLC equipped with 2 LC-
10AT pumps, a SPD-M10AVP photodiode array detector, a Flow
Count PIN diode radiodetector from BioScan and a Waters Atlantis
T3 column (6 250 mm, 5 mm). A gradient of 95:5!0:100 H2O/
CH3CN supplemented with 0.1% TFA over 18 min at 1 mLmin
 1
was used. For preparative HPLCs, a Phenomenex Jupiter (250 
100 mm, 5 mm), and flowrates of 5 mLmin
 1 were used.
Radioactivity measurements were performed with a Cap-
intec CRC1243 Dose Calibrator (Capintec, Ramsay, NJ,
USA). For TLC measurements with radioactive materials,
a Bioscan AR2000 (Bioscan, Inc., Washington, DC, USA)
was used. Microwave irradiations were carried out using
a Biotage Initiator microwave synthesizer (Biotage, LLC,
Charlotte, NC, USA). LRMS were recorded with a Waters
Acquity UPLC with electrospray ionization SQ detector
(ESI). HRMS were recorded with a Waters LCT Premier
system (ESI).
1H NMR spectra were recorded on a Bruker
AVIII (500 MHz) spectrometer. Chemical shifts for protons
are reported in parts per million (ppm) and are refer-
enced against the residual proton resonance of deuterat-
ed solvents (CDCl3:
1H, 7.26 ppm; [D4]MeOH:
1H,
3.31 ppm; [D4]DMSO:
1H, 2.50 ppm). NMR data are re-
ported as follows: chemical shift, multiplicity (s=singlet,
d=doublet, t=triplet, m=multiplet), coupling constants
(Hz) and integration.
Synthesis
3-(4-Phenylacetic acid)-1,2,4,5-tetrazine succinimidyl
ester (Tz-NHS): N-Hydroxysuccinimide (163 mg,
1.42 mmol) and Et3N (495 mL, 3.55 mmol) were added to
a mixture Tz-COOH (150 mg, 0.71 mmol) and N-(3-dime-
thylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDCI,
544 mg, 2.84 mmol) in CH2Cl2 (15 mL), and the reaction mixture
was stirred for 6 h at RT. The mixture was extracted with acetic
acid (1m, 2 10 mL) and H2O (2 10 mL), dried (MgSO4), and vola-
tiles were removed in vacuo. The crude product was purified by
column chromatography (CH2Cl2/MeOH, 97.5:2.5), yielding Tz-NHS
as a pink solid (67.3 mg, 0.22 mmol, 31%):
1H NMR (500 MHz,
[D4]MeOH): d=10.60 (s, 1H), 8.51 (d, J=8.3, 2H), 7.55 (d, J=8.3,
2H), 7.20 (d, J=7.7, 1H), 4.32 (s, 2H), 2.36 (s, 4H); LC–MS (ESI ):
m/z (%): 313.1 (100) [M H]
 , 312.1 (100) [2M H]
 .
N
2-(tert-Butoxycarbonyl)-N
6-(tetrazine)-l-lysine (Boc-t-OH, 1): Tz-
NHS (55.0 mg, 0.18 mmol) was dissolved in a mixture of Boc-l-Lys-
OH (53.2 mg, 0.36 mmol) and Et3N (63 mL, 0.45 mmol) in MeOH
(6 mL) and stirred for 2 h. The reaction mixture was dried in vacuo,
and the resulting crude product purified by column chromatogra-
phy (5–25% MeOH in CH2Cl2), yielding 1 as a pink film (40.3 mg,
0.09 mmol, 50%):
1H NMR (500 MHz, [D4]MeOH): d=10.31 (s, 1H),
8.55 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 4.05 (dd, J=8.7,
4.7 Hz, 1H), 3.22 (t, J=6.9 Hz, 2H), 1.86–1.61 (m, 2H), 1.58–1.38 (m,
13H); LC–MS (ESI+): m/z (%): 467.3 (30) [M+Na]
+, 911.6 (10)
[2M+Na]
+; LC–MS(ESI ): m/z (%): 443.3 (10) [M H]
 , 887.6 (20)
[2M H]
 ; HRMS (ESI) m/z [M+Na]
+calcd for C21H28N6O5Na:
467.2005, found: 467.2019.
Methyl N
2-(tert-butoxycarbonyl)-N
6-(tetrazine)-l-lysinate (Boc-t-
OMe, 2): N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydro-
chloride (51.8 mg, 0.27 mol) was added to a mixture of 3-(4-phenyl-
acetic acid)-1,2,4,5-tetrazine succinimidyl ester (20 mg, 0.09 mmol),
Boc-l-Lys-OH (28.6 mg, 0.11 mmol), Et3N (63 mL, 0.45 mmol) in
CH2Cl2 (5 mL), and the reaction mixture was stirred over night at
RT, before it was dried in vacuo. The resulting crude product was
purified by column chromatography (5% MeOH in DCM), yielding
2 as a pink film (20.8 mg, 0.05 mmol, 56%):
1H NMR (500 MHz,
[D6]DMSO): d=10.57 (s, 1H), 8.44 (d, J=8.2, 2H), 8.13 (t, J=5.5 Hz,
1H), 7.55 (d, J=8.2 Hz, 2H), 7.20 (d, J=7.7 Hz, 1H), 3.93–3.88 (m,
1H), 3.61 (s, 3H), 3.55 (s, 2H), 3.05 (q, J=6.5 Hz, 2H), 1.65–1.52 (m,
2H), 1.43–1.27 (m, 13H); LC–MS (ESI+) m/z (%): 359.3 (75)
Figure 2. Chemically orthogonal synthesis of
89Zr-VFtAG (6). A) Synthesis and structure of
6, product of the chemically orthogonal reaction of VFtAG (4) with
89Zr-TCO (5); Reaction
conditions:C H 3CN/H2O (1:1, 0.1% TFA), 30 min. B) Radio-HPLC trace of 5. C) Radio-HPLC
trace of 6.
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+, 459.3 (40) [M+H]
+, 917.7 (30) [2M+H]
+; HRMS
(ESI): m/z [M+H]
+ calcd for C22H30N6O5Na: 481.2171, found:
481.2175.
N
6-(tetrazine)-l-lysine (H-t-OH, 3): Boc-t-OH 1 (10 mg, 22.5 mmol)
was dissolved in a mixture of TFA/CH2Cl2 (1:1) and vigorously
stirred for 1.5 h. Volatiles were removed in vacuo, and the resulting
crude material purified using HPLC, yielding 3 as a pink solid
(5.6 mg, 16.3 mmol, 72%):
1H NMR (500 MHz, [D4]MeOH): d=10.32
(s, 1H), 8.55 (d, J=8.3, 2H), 7.57 (d, J=8.3, 2H), 3.92 (t, J=6.3, 2H),
3.65 (s, 2H), 3.24 (dt, J=6.3, 3.2 Hz, 2H), 2.00–1.84 (m, 2H), 1.62–
1.42 (m, 2H); LC–MS (ESI+): m/z (%): 345.2 (100) [M+H]
+, 367.2
(15) [M+Na]
+; HRMS (ESI): m/z [M+H]
+ calcd for C16H21N6O3:
345.1668, found: 345.1675.
Pentapeptide GAtFV (4): The synthesis was carried out on a 0.01–
0.02 mmol scale in a fritted syringe (3 mL volume), using a Merri-
field resin, which was preloaded with Boc-Gly-OH (20 mg, 0.5–
1.0 mmolg
 1). The resin was swollen by washing with DMF (2 
2 mL) and CH2Cl2 (2 2 mL). Na-Boc groups were removed by addi-
tion of a solution of TFA/CH2Cl2 (1:1; 1 5 min, 2 mL and 1 
20 min, 2 mL), followed by washing with CH2Cl2 (2 2 mL) and
DMF (2 2 mL). Amino acids were coupled (1 h, RT) without prior
neutralization of the resin using a freshly prepared mixture of BOP
(0.04 mmol, 18 mg), H nig’s base (N,N’-diisopropylethylamine,
DIEA; 0.12 mmol, 16 mg) and amino acid (0.08 mmol) in DMF
(2.5 mL). After coupling, the resin was washed with DMF (3 2 mL)
and CH2Cl2 (3 2 mL). After completion of the deprotection/cou-
pling sequence, the peptide was transferred to a microwave vessel,
suspended in a solution of TFA/H2O (97.5:2.5, 500 mL), and micro-
waved (2 5 min, 50 Hz). The resin was removed by filtration and
Et2O (10 mL) added to the supernatant. The resulting crude precipi-
tate was filtered and purified using HPLC to yield 4 as a pink solid
(0.9 mg, 1.3 mmol, 7% yield): LC–MS (ESI+): m/z (%): 719.5 (20)
[M+H]
+; LC–MS (ESI ): m/z (%): 717.5 (10) [M H]
 ; HRMS (ESI):
m/z calcd for [M+H]
+ C35H47N10O7: 719.3633, found: 719.3629.
trans-Cyclooctene–desferrioxamine conjugate (TCO–DFO): TCO-
NHS (12 mg, 45 mmol) was added to a solution deferrioxamine me-
sylate salt (20 mg, 30 mmol) and Et3N (21 mL, 0.15 mmol) in CH3CN/
H2O (1:1, 1 mL) and stirred at RT for 90 min. Subsequently, volatiles
were removed in vacuo, and the crude product was purified using
HPLC, yielding TCO–DFO as a white solid (6.6 mg, 9 mmol, 30%):
1H NMR (500 MHz, [D6]DMSO): d=9.68–9.54 (m, 2H), 7.78–7.74 (m,
1H), 6.93–6.88 (m, 1H), 5.60–5.40 (m, 2H), 4.21–4.17 (m, 1H), 3.48–
3.41 (m, 6H), 3.03–2.87 (m, 6H), 2.61–2.53 (m, 4H), 2.29–2.21 (m,
7H), 1.96 (s, 3H), 1.91–1.85 (m, 4H), 1.56–1.15 (m, 22H); LC–MS
(ESI+): m/z (%): 357.4 (10) [M+2H]
2+, 713.6 (100) [M+H]
+, 735.5
(70) [M+Na]
+, 759.4 (10) [M+HCOO]
+; HRMS (ESI): m/z calcd for
[M+H]
+ C34H61N6O10: 713.4474, found: 713.4449.
89Zr-trans-cyclooctene (
89Zr-TCO, 5):[
89Zr]Zr-oxalate (59.2–74 MBq,
1.600–2.000 mCi) in oxalic acid (1.0m, 150 mL) was adjusted to
pH 7.2–8.0 with Na2CO3 (1.0m,  150 mL). After the evolution of
CO2(g) stops, the
89Zr was added to a solution of TCO–DFO (1 mm,
100 mL) in PBS/DMSO (9:1). The reaction solution was stirred at
378C for 30 min, before the reaction progress was assayed using
instant thin-layer chromatography (ITLC) with an eluent of 1m
citric acid. In the ITLC experiments,
89Zr-TCO remains at the base-
line, while free
89Zr
4+ ions and other [
89Zr]-citrate complexes elute
with high Rf values. The crude reaction mixture was purified using
HPLC, and volatiles were removed in vacuo, yielding 5 in >98% ra-
diochemical purity, 39% uncorrected isolated radiochemical yield
(RCY), and a specific activity of >5.59 mCimmol
 1 (n=3).
89Zr-GAtFV (6):G A tFV (4, 20 nmol, 20 mL, 1 mm in DMSO) was
added to
89Zr-TCO (56 mCi, 10 mL, 5.56 mCimL
 1 in 1:1 CH3CN/H2O
with 0.05% TFA), and the mixture was agitated at RT for 20 min,
before purification using HPLC, yielding 6 in >95% purity, 65%
uncorrected isolated RCY, and a specific activity of >3.00 mCim
mol
 1 (n=3).
Tetrazine stability determination
Boc-deprotection conditions: TFA (760 mL) was added to a solution
of 3 (5 mm,2 0mL, DMSO) and coumarin (5 mm,2 0mL, DMSO) and
the resulting mixture stirred at room temperature. A control
sample consisted of DMSO (760 mL), which was added to a solution
of 3 (5 mm,2 0mL, DMSO) and coumarin (5 mm,2 0mL, DMSO). The
amount of 3 relative to coumarin was measured at t=0, 0.5, 1, 2,
3, 4, 5, 6, 7, 8 and 9 h using HPLC analysis, and the results were
compared to the control sample. All measurements were per-
formed in triplicate.
Coupling conditions: Solutions of (benzotriazol-1-yloxy)tris(dime-
thylamino)phosphonium hexafluorophosphate (BOP, 10 mm,2 5mL,
DMF) and DIEA (100 mm,2 5mL, DMF) were added to a solution of
2 (5 mm,2 5mL, DMF) and coumarin (5 mm,2 5mL, DMF). A control
sample consisted of DMF (50 mL), which was added to a solution of
2 (5 mm,2 5 mL, DMF) and coumarin (5 mm,2 5 mL, DMF). The
amount of 3 relative to coumarin was measured at t=0, 0.5, 1 h,
2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h and 9 h using HPLC analysis, and the
results were compared to the control sample. All measurements
were performed in triplicate.
Resin-cleavage conditions: TFA (950 mL) and deionized H2O
(25 mL) were added to a solution of 3 (5 mm,2 0mL, DMSO) and
coumarin (5 mm,5mL, DMSO), and the resulting mixture was ex-
posed to sequential microwave irradiation intervals (0–11 2.5 min,
50 W). A control sample consisted of DMSO (975 mL), which was
added to a solution of 3 (5 mm,2 0 mL, DMSO) and coumarin
(5 mm,5mL, DMSO). At the end of each microwave irradiation in-
terval, a sample was drawn, the amount of 3 relative to coumarin
was measured using HPLC analysis, and the results were compared
to the control sample. All measurements were performed in tripli-
cate.
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